No Data
No Data
Noile-Immune Biotech: Confirmation
Noile-Immune Biotech: Quarterly Report - 10th Quarter 1st Quarter (2024/01/01 - 2024/03/31)
Noile-Immune Biotech: Summary of financial results for the 1st quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
The TSE Growth Index continues to rise, and although sales continue to be weak, buybacks take precedence
TSE Growth Market Index 830.23 +4.39/ Volume 72.93 million shares/ trading price 77.8 billion yen TSE Growth Market 250 Index 647.40 +2.79/ turnover 44.77 million shares/ trading price 54.7 billion yen Today's growth market continues to grow with both the TSE Growth Market Index and the TSE Growth Market 250 Index. The number of rising stocks is 322, the number of falling stocks is 214, and 37 unchanged. The US stock market continued to rise on the 29th. The Dow Jones Industrial Average rose by $146.43 (+ 0.38%)
Neurimune, etc. [strange brands seen from changes in trading volume]
Stock closing price turnover compared to the previous day*<4893>Neil Immune 173 12 12164900*<6822>Oi Electric 2021 180 91000*<4558>Chukyo Pharmaceutical 209 2 152400*<4772>Stream M 136 0 1651800*<1867>Ueki Gumi 1626 47 126900*<15
3 points to pay attention to in the backstage -- strong wait-and-see attitude ahead of announcing the results of the Bank of Japan meeting
I would like to pay attention to the following 3 points in the late-day transaction on the 26th. ・The Nikkei Average rebounded, waiting to announce the results of the Bank of Japan meeting and the Nikkei Average rebelled against a strong wait-and-see attitude · The dollar and yen are fighting, the Bank of Japan is awaiting policy announcements and the top contributor to price increases is Tokyo Electron <8035>, the same 2nd place is SoftBank G<9984>■The Nikkei Average rebounds against a strong wait-and-see attitude ahead of announcing the results of the Bank of Japan meeting. 37780.35 yen (estimated turnover 70,400 million), 151.87 yen higher (+0.40%) compared to the previous day
No Data